RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Medbanks Network Technology, a Beijing oncology database company, completed a $59 million Series D funding, led by CLP Fund and CDH Investments. Medbanks is building a China-specific tumor data platform that it considers state-of-the-art. It is aimed at serving clinicians, scientists and pharmas. Established in 2014, the company uses “sky eye hardware” to collect data from multiple China cancer centers, which follow a patient through the whole course of cancer treatment, from diagnosis to follow-up.
Source: China Biotoday
